Every Form 4 that Pelthos Therapeutics Inc. (PTHS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PTHS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTHS filings page.
Pelthos Therapeutics director Ezra M. Friedberg reported small, pre-planned share sales and updated his holdings. He sold a total of 558 shares of Pelthos Therapeutics common stock in open-market transactions on July 2, 2026, including 534 shares at a weighted average price of $26.0303 and 24 shares at a weighted average price of $27.3254. According to a footnote, these sales were executed under a Rule 10b5-1 plan adopted on December 16, 2025 to satisfy estimated tax obligations from the vesting of restricted stock units granted by the company.
After these sales, Friedberg continues to hold Pelthos Therapeutics shares both directly and indirectly. Indirect holdings include 40,000 shares held by Key Recovery Group LLC and 82,072 shares held by Balmoral Financial Group LLC. Friedberg is the manager of both entities and may be deemed to beneficially own those shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
Pelthos Therapeutics Inc. director Matthew Pauls reported selling 786 shares of Common Stock in open-market transactions on July 2, 2026. The sales occurred at weighted average prices of about $26 per share across multiple trades.
According to the disclosure, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025 to help satisfy estimated tax obligations tied to the vesting of restricted stock units granted by Pelthos. After the transactions, Pauls directly held 14,364 shares of Pelthos common stock.
Pelthos Therapeutics Inc. director Peter Greenleaf reported open-market sales of a total of 797 shares of Common Stock on July 2, 2026. The trades were executed at weighted average prices of about $25.9954 and $27.2733 per share in multiple transactions.
According to the disclosure, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025 to help satisfy estimated tax obligations tied to vesting of restricted stock units. Following the transactions, Greenleaf directly holds 23,884 shares of Pelthos Therapeutics Common Stock.
Pelthos Therapeutics Inc. director Ezra M. Friedberg reported small open-market sales of common stock alongside updated indirect holdings. On June 15, 2026, he sold 59 shares at $27.9403 per share and 224 shares at $27.1245 per share in open-market transactions.
According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 plan adopted on December 16, 2025 to satisfy estimated tax obligations from vesting restricted stock units. After the sales, he held 81,600 shares directly and indirectly 40,000 shares via Key Recovery Group LLC and 82,072 shares via Balmoral Financial Group LLC.
Pelthos Therapeutics director Todd C. Davis reported open-market purchases of Pelthos common stock. On June 11, 2026, he bought a total of 35,948 shares in two transactions, at weighted average prices of $27.8046 and $28.7261 per share. Following these trades, his direct holdings increased to 75,834 common shares. The filing also shows 1,500,000 Pelthos shares held indirectly by Ligand Pharmaceuticals Incorporated, where Davis serves as Chief Executive Officer and director; he may be deemed to beneficially own these shares but disclaims beneficial ownership beyond his pecuniary interest.
Pelthos Therapeutics Inc.’s Form 4 details equity changes tied to Chief Financial Officer Francis Knuettel II’s separation. A Separation Agreement dated May 15, 2026 governs forfeiture and accelerated vesting of his stock awards.
The filing reports the forfeiture and cancellation of unvested restricted stock units and stock options for no consideration, and the acceleration of vesting for 19,525 RSUs out of 33,472 previously granted under the 2023 Equity Incentive Plan. Certain stock options also became fully vested and exercisable, while others were cancelled.
Separately, the Lara Knuettel Revocable Trust, an entity associated with Mr. Knuettel, sold 1,500 shares of common stock on May 22, 2026 in open-market trades at a weighted average price of $26.8433 per share, leaving 11,316 shares held by the trust and 10,000 shares held by Camden Capital LLC.
Pelthos Therapeutics Inc. director Ezra M. Friedberg reported a small tax-related share disposition. On May 14, 2026, 144 shares of common stock were disposed of at a weighted average price of $27.007 per share to satisfy estimated tax obligations tied to vesting restricted stock units.
The filing states these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. After this transaction, Friedberg directly holds 81,883 common shares, and he is also the manager of entities that hold 40,000 shares (Key Recovery Group LLC) and 82,072 shares (Balmoral Financial Group LLC), which he may be deemed to beneficially own only to the extent of his pecuniary interest.
Pelthos Therapeutics Inc. director Richard Malamut reported small open-market sales of company stock. On April 2, 2026, he sold 310 shares of Common Stock at a weighted average price of $20.5126 per share and 280 shares at a weighted average price of $21.3612 per share. A footnote states these sales were made under a pre-arranged Rule 10b5-1 plan adopted on December 16, 2025, to satisfy estimated tax obligations tied to vesting of restricted stock units granted by the company. After the transactions, he held 27,422 shares directly and 1,040 shares indirectly, jointly with his spouse.
Pelthos Therapeutics director Ezra M. Friedberg reported small open‑market sales of Pelthos common stock. On April 2, 2026, he sold 293 shares at $20.5121 and 265 shares at $21.3612, totaling 558 shares. These transactions were made under a Rule 10b5-1 trading plan adopted on December 16, 2025 to help cover estimated tax obligations from vesting restricted stock units.
After the sales, Friedberg held 82,027 common shares directly82,072 shares held indirectly by Balmoral Financial Group LLC and 40,000 shares held indirectly by Key Recovery Group LLC, entities for which he is manager and may be deemed a beneficial owner to the extent of his pecuniary interest.
Pelthos Therapeutics Inc. director Matthew Pauls sold 786 shares of Common Stock in open-market transactions. The sales occurred on April 2, 2026 at weighted average prices of $20.5154 and $21.3628 per share.
According to the disclosure, the transactions were made under a pre-arranged Rule 10b5-1 plan adopted on December 16, 2025 to satisfy estimated tax obligations tied to vesting of restricted stock units granted by Pelthos Therapeutics Inc. After these trades, Pauls directly holds 15,150 shares of Common Stock.
Pelthos Therapeutics Inc. director Peter Greenleaf reported selling a total of 797 shares of Common Stock in two open-market transactions on April 2, 2026. He sold 420 shares at a weighted average price of $20.5151 and 377 shares at $21.3614. According to the disclosure, these sales were made under a pre-arranged Rule 10b5-1 plan adopted on December 16, 2025, to help cover estimated tax obligations tied to vesting restricted stock units. After the transactions, Greenleaf directly holds 24,681 shares of Pelthos Therapeutics common stock.
Friedberg Ezra M reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics director Ezra M. Friedberg reported amended share awards tied to board compensation. The Form 4/A reclassifies prior filings so that restricted stock units (RSUs) granted under the 2023 Equity Incentive Plan now appear in the non-derivative table, each RSU delivering one share of common stock as it vests.
RSU awards cover 19,108 shares on July 2, 2025, 2,454 shares on November 13, 2024, and 6,450 shares on June 14, 2024, all at a stated price of $0.00 per share as compensation. These RSUs vest in equal quarterly installments over three years, subject to continued service. After the most recent award, Friedberg directly holds 82,585 common shares, with additional indirect holdings reported as 82,072 shares through Balmoral Financial Group LLC and 40,000 shares through Key Recovery Group LLC, which he may be deemed to beneficially own but disclaims except for his pecuniary interest.
Davis Todd C reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Todd C. Davis filed an amended insider report to reclassify prior equity awards as common stock grants rather than derivative holdings. The amendment covers restricted stock units (RSUs) granted under the company’s 2023 Equity Incentive Plan, each RSU settling into one share of common stock.
The filing reports grants of 19,108, 4,961 and 12,900 shares of common stock, all received as compensation for service on the board. These RSUs vest in equal quarterly installments over three years, conditioned on continued service. After these grants, Davis directly holds 39,886 common shares.
The amendment also notes an indirect holding of 1,500,000 shares recorded in the name of Ligand Pharmaceuticals Incorporated, where Davis serves as Chief Executive Officer and director. He may be deemed a beneficial owner of those shares but expressly disclaims beneficial ownership except to the extent of his pecuniary interest. All amounts have been adjusted for a 1-for-10 reverse stock split effective July 1, 2025.
Malamut Richard reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Richard Malamut filed an amended Form 4 to reclassify previously reported equity awards. The filing reports grants of 6,450, 19,108, and 2,454 shares of Common Stock at a price of $0.00 per share, reflecting restricted stock units (RSUs) issued under the company’s 2023 Equity Incentive Plan.
Each RSU represents the right to receive one share of Common Stock and vests in equal quarterly installments over three years, contingent on continued board service. The share amounts have been adjusted for the company’s 1-for-10 reverse stock split effective July 1, 2025. Following these awards, Malamut is shown with 28,012 directly held shares and an additional 1,040 shares indirectly held jointly with his spouse.
Plesha Scott M. reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. CEO and President Scott M. Plesha reported an equity compensation grant tied to restricted stock units. The Form 4 amendment shows an award of 83,678 shares of Common Stock, issuable upon settlement of RSUs granted under the company’s 2023 Equity Incentive Plan.
Each RSU represents one share of Common Stock and may be settled only in shares, subject to vesting. One-third of the RSUs vest on July 2, 2026, with the remaining balance vesting in equal quarterly installments over the following two years, contingent on continued service. Following this grant, Plesha holds 83,678 shares directly.
This filing amends a prior Form 4 by reclassifying the original RSU grant from the derivatives table to the non-derivative common stock table, clarifying how the award is reported rather than changing the underlying compensation terms.
Greenleaf Peter reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Peter Greenleaf reported an award of 25,478 shares of Common Stock, received as a grant of restricted stock units under the company’s 2023 Equity Incentive Plan. The award was granted as compensation for his service on the board of directors, at a stated price of $0.00 per share.
The RSUs vest over time: one-third of the underlying shares vested on July 2, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to continued service. Following this grant, Greenleaf directly holds 25,478 shares of Common Stock from this award.
Pauls Matthew reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Matthew Pauls reported an amended insider filing showing an equity award linked to 25,478 shares of common stock. These shares are issuable upon settlement of restricted stock units granted under the company’s 2023 Equity Incentive Plan as compensation for his board service.
The RSUs vest over time: one-third of the underlying shares vested on July 2, 2025, with the remaining units vesting in equal quarterly installments over two years, subject to his continued service. Following this grant, Pauls holds 25,478 shares of common stock directly.
Rangarao Sai reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. Chief Commercial Officer Rangarao Sai reported an amended insider filing reflecting an award of 30,518 shares of Common Stock, received as compensation in the form of restricted stock units (RSUs) under the company’s 2023 Equity Incentive Plan.
Each RSU represents the right to receive one share of Common Stock, settled solely in shares. One-third of the RSUs vests on July 2, 2026, with the remaining units vesting in equal quarterly installments over the following two years, contingent on Mr. Sai continuing in service. Following this grant, he directly holds 30,518 shares.
Baxter Richard B reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Richard B. Baxter reported an amended Form 4 reflecting a grant of 19,108 shares of Common Stock, issued at $0.00 per share upon settlement of previously granted restricted stock units (RSUs).
The RSUs were granted as compensation for his service on the board under the company’s 2023 Equity Incentive Plan. They vest in equal quarterly installments over three years, contingent on his continued service, and are settled solely in shares of Common Stock.
Francis Knuettel II reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. reported that its CFO, Treasurer and Secretary, Francis Knuettel II, received a grant of 33,472 restricted stock units (RSUs), each representing one share of common stock under the company’s 2023 Equity Incentive Plan. The RSUs were granted as compensation for his service as an officer and may be settled solely in shares of common stock, subject to vesting.
The RSUs vest with one-third of the shares on July 2, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, contingent on continued service. The filing also shows indirect holdings of common stock by Camden Capital LLC (10,000 shares) and the Lara Knuettel Revocable Trust (12,816 shares); Knuettel may be deemed to beneficially own these shares but disclaims beneficial ownership except for his pecuniary interest. Share amounts reflect a 1-for-10 reverse stock split effective July 1, 2025.
Pelthos Therapeutics Inc. reported an equity compensation grant to director Andrew J. Einhorn. On December 23, 2025, he was awarded 12,000 Restricted Stock Units (RSUs) of Pelthos common stock under the company’s 2023 Equity Incentive Plan, as amended and restated effective April 16, 2025. Each RSU represents a contingent right to receive one share of common stock with a par value of $0.0001 per share. The RSUs are scheduled to vest on January 1, 2027, meaning the shares will be delivered only if the vesting conditions tied to board service are satisfied.
Pelthos Therapeutics Inc. reported insider activity involving a senior secured convertible note held by a 10% owner and director-by-deputization. On November 6, 2025, Pelthos issued a $9,000,000 senior secured convertible note to the reporting person, initially convertible into common stock at $34.442 per share, with a 49.9% beneficial ownership limitation.
At the December 17, 2025 annual shareholder meeting, shareholders approved waiving NYSE American rules limiting the number of shares issuable in this private placement. As a result, the conversion price of the note was reduced from $34.442 per share to $29.73 per share, which the Form 4 reports as the cancellation of the original note and acquisition of a new note. The derivative securities table shows 261,309 and 302,724 shares of common stock underlying the note at the two conversion prices.
Pelthos Therapeutics Inc. director Matthew Pauls reported equity transactions in a Form 4. On July 2, 2025 and October 2, 2025, restricted stock units (RSUs) previously granted to him vested and were converted into 8,493 and 2,123 shares of common stock, respectively, at a price of $0 per share, reflecting the nature of RSU settlements. These vestings are part of a 25,478-RSU grant made on July 2, 2025, with one-third vesting immediately and the rest quarterly over two years.
On December 10, 2025, he made a gift of 9,542 shares of common stock to the GP 2024 Trust for no consideration, reducing his directly held common stock to 1,074 shares. Pauls states he is not a trustee, does not control voting or investment decisions for the trust, and disclaims beneficial ownership of those gifted shares except for any pecuniary interest. After these transactions, he also reports continued holdings of unvested or outstanding RSUs.
Pelthos Therapeutics Inc. director reports stock sales through entities
Director Ezra M. Friedberg reported several open market sales of Pelthos Therapeutics Inc. (PTHS) common stock on 11/25/2025. Through Balmoral Financial Group LLC, he reported multiple sale transactions of common stock at prices ranging from $28.00 to $28.50 per share, including individual trades of 5,999 shares at $28.00, 2,000 shares at $28.135, 1 share at $28.50, and 2,000 shares at $28.005.
Following these transactions, the filing shows 30,000 shares of common stock beneficially owned indirectly through Balmoral Financial Group LLC, 40,000 shares indirectly through Key Recovery Group LLC, and 54,573 shares held directly. The filing notes that Mr. Friedberg is the manager of both Balmoral and Key and may be deemed to beneficially own the shares they hold, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Pelthos Therapeutics (PTHS) reported an insider transaction on a Form 4. On 11/06/2025, a reporting person identified as both a Director and 10% Owner acquired a senior secured convertible note with an aggregate principal amount of $9,000,000.
The note may be converted into common stock at a conversion price of $34.442 per share, corresponding to 261,309 underlying shares if fully converted. The instrument includes a beneficial ownership limitation of 49.9% with respect to the reporting person. The filing lists the security as acquired and directly owned.